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was awake and fully oriented. Her mental status, cranial nerves,
and deep tendon reflexes all were normal. Examination of the
heart and lungs was normal. Her abdomen showed tenderness
to deep palpation in the right upper quadrant and over the
lower quadrants. The skin was normal and showed no obvious
signs of dehydration. She had no ankle edema. Laboratory stud-
ies revealed: serum sodium concentration, 140 mmol/L; serum
creatinine, 147 mol/L (1.7 mg/dL); urea, 14.8 mmol/L; total
porphyrin, 0.53 mg/L (normal, 0.3 mg/L); and delta-amino-
levulinic acid, 317 mol/L (normal, 220 mol/L). Urinary
porphobilinogen was 20.3 mg/24 h (normal,1.9 h); and delta-
amino-levulinic acid, 17.5 mg/24 h (normal, 6.1 mg/24 h).
On admission the patient was given 3.6 L of 10% glucose/
day intravenously (IV). These infusions were supplemented
with 40 mmol of NaCl/L of infusate, but her pain failed to dis-
appear under this regimen. Her nausea continued and sheCASE PRESENTATION
vomited three to five times per day. Gastroscopy was unre-
A 31-year-old white woman was admitted to the hospital be- markable. On the 3rd hospital day, the serum sodium concentra-
cause of diffuse cramping abdominal pain. The pain was associ- tion was 132 mmol/L. On the 5th hospital day, the vomiting
ated with nausea, vomiting, and an inability to eat or hold down intensified. She became somnolent and confused. The serum
fluids. One week prior to admission, the patient had rhinitis.
sodium concentration was 115 mmol/L. The creatinine concen-The day of admission coincided with the patient’s onset of
tration was 133mol/L (1.5 mg/dL), the urea concentration wasmenstrual bleeding.
13.9 mmol/L, and the glucose concentration was 9.6 mmol/L.Her medical history revealed 30 hospital admissions over the
On the 7th hospital day, the patient vomited multiple times.previous six years for acute intermittent porphyria. During pre-
Her regimen of glucose infusions supplemented by NaCl wasvious attacks of porphyria, the physical examination had shown
continued at 3.6 L/day. She was agitated and confused, anddiffuse abdominal tenderness and a diminution or absence of
she was periodically unable to speak. On the 8th hospital day,bowel sounds. A neurologist had documented that the patient
the serum sodium concentration had fallen to 97 mmol/L. Thecould not extend the fingers of both hands completely. Other-
patient had a grand mal seizure. A cerebral computed tomogra-wise, the physical examination had been unremarkable. Also,
phy scan (CCT) demonstrated symmetrically small ventriclesthe patient’s routine laboratory tests generally had been nor-
and “blurring of sulci,” findings suggestive of cerebral edema.mal, except that she had elevated excretion of protoporphyrins
An infusion of 10% NaCl corrected the severe hyponatremiaand porphyrins multiple times, both during exacerbations of
from 98 mmol/L to 128 mmol/L within 36 hours (Fig. 1).the porphyria as well as during remission. Neither cimetidene
On the 13th hospital day, a second CCT was unremarkable.nor luteinizing hormone-releasing hormone (LHRH) improved
After the rapid correction of the hyponatremia, the patient atthe porphyria. Her exacerbations usually were treated with
first continued to be somnolent, unable to communicate, andglucose infusions and meperidine. Otherwise, her medical, fam-
apparently confused. She had a tremor of her hands. Her at-ily, and social histories were unremarkable.
tempts at speaking showed a scanning rhythm. The consultingPhysical examination disclosed that she was in acute distress
neurologist did not find any cranial nerve disturbances, diffi-from severe pain. Her blood pressure was 130/100 mm Hg; pulse
culty swallowing, evidence of pseudobulbar palsy, or abnormal-rate, 110 beats/min and regular; and temperature, 36.3C. She
ities of the deep tendon reflexes. The intravenous infusions of
10% glucose had been discontinued. No fluid restriction was
ordered; the chart documented that daily fluid consumption
The Nephrology Forum is funded in part by grants from Amgen,
ranged between 1 and 2 liters. The abdominal pain, the nausea,Incorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo-
and the vomiting disappeared between days 10 and 14.rated; and Bristol-Myers Squibb Co.
From day 14 onwards, she began to communicate somewhat
Key words: porphyria, vasopressin antagonists, cerebral edema, aqua- better. An electroencephalogram (EEG) obtained on the 16th
porins, central pontine myelinolysis, blood-brain barrier, aquaresis. hospital day showed generalized changes of moderate severity
together with frontotemporal slowing. The patient was given 2001 by the International Society of Nephrology
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Fig. 1. Course of the serum sodium concentration presented over the first 11 days of hospitalization. The horizontal bars at the top of the diagram
indicate the treatment given to the patient. The normal range of serum sodium concentration of the laboratory was 136 mmol/L to 149 mmol/L.
Table 1. Signs and symptoms of hyponatremiaintensive physical rehabilitation therapy. A neurologic consulta-
tion on day 35 disclosed that the patient was occasionally con- Mild Anorexia, nausea, vomiting, weakness, muscle cramps,
fused, although mostly awake and alert; she communicated fre- headache, difficulty in concentrating, impaired memory
quently. She still exhibited occasional episodes of unfounded Severe Confusion, hallucinations, obtundation, urinary and fecal
agitation. Neurologic consultation on the 60th hospital day re- incontinence, respiratory insufficiency, coma, decorti-
vealed a reduced ability to concentrate. An EEG on the 65th hos- cate or decerebrate posturing, generalized seizures,
respiratory arrestpital day showed only mild irregularities of the alpha rhythm.
During the neurologic consultation on the 70th hospital day, the
patient complained of difficulty memorizing and concentrating.
However, she was generally judged to be stable and improved. glucose solution given to treat the porphyria. Her physi-
On the 80th day of hospitalization, the patient was discharged cians failed to react to the worsening hyponatremia untilhome. The serum sodium concentration had ranged between
she had diffuse cerebral edema and a grand mal seizure.140 to 146 mmol/L from day 10 onwards. The discharge plasma
The hyponatremia was corrected at a rate of 0.9 mmol/creatinine concentration was 88 mol/L (1.0 mg/dL); urea was
L/h. A computerized axial tomogram (CT) disclosed no4.7 mmol/L. The urinary excretion rates of delta-amino-levu-
linic-acid and that of total porphyrin remained elevated. evidence of (central pontine) myelinolysis. The patient
had hyponatremic encephalopathy with permanent physi-
cal disability resulting from the cerebral edema.
DISCUSSION
Acute severe hyponatremiaProf. Dr. Peter Gross (Schwerpunkt Professor fu¨r
Nephrologie, Medizinische Klinik III und Medizinische Severe hyponatremia is arbitrarily defined as a serum
Poliklinik, Universita¨tsklinikum Carl Gustav Carus, Dres- sodium concentration 115 mmol/L [5, 6]. The designa-
den, Germany): This patient’s severe symptomatic hypo- tion “acute” refers to a duration of 36 to 48 hours. This
natremia was related to an attack of acute intermittent condition commonly occurs after surgery [7]. In that set-
porphyria. Although porphyria, vomiting and abdominal ting, previously asymptomatic patients who receive large
pain all cause non-osmotic ADH release [1–4], the over- amounts of hypotonic fluid (3 to 8 L/12 to 24 h) can de-
riding stimulus of antidiuretic hormone (ADH) in this pa- velop neurologic signs of increasing severity (Table 1)
tient probably was plasma volume contraction. The hypo- [8]. If the hyponatremia is progressive, obtundation, con-
fusion, coma, generalized seizures, and respiratory arrestnatremia was precipitated by voluminous amounts of
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Fig. 2. Axial computer tomographic (CT)
scans of the brain showing a normal study (A)
and brain edema (B). Note the diminution of
the size of the ventricles in B; in addition, the
sulci of the brain are no longer demonstrable
in panel B (CTs were kindly provided by Dr.
V. Ha¨nig, U.K.D., Dresden, Germany).
can occur [8]. Imaging studies usually demonstrate brain that mice deficient in AQP-4 manifest reduced cerebral
edema upon hypo-osmotic challenge [24]. Compensationedema (Fig. 2). Autopsy studies have revealed: diffuse
cerebral edema, edema of the brain stem, obliteration for swelling ensues rapidly, comprising decreased cere-
bral venous pooling and loss of cerebral spinal fluid fromof sulci, and herniation of the brain stem into the foramen
magnum [9]. This acute hyponatremic syndrome also can the brain [8, 10]. The finding that young age appears to
be a risk factor for brain edema might be explained by theoccur in psychotic patients with polydipsia, labor and
delivery in the presence of high doses of oxytocin given relatively smaller cerebral spinal fluid spaces in young as
compared to old brains. Within 5 minutes, cell volume-with hypotonic fluids, child abuse involving forced water
intake, patients receiving thiazides, and marathon run- regulatory ions (Na, K, Cl) are released from brain
cells [25]; this efflux can last as long as four hours. Stretchners [8–14]. The consequences of acute hyponatremia
are more serious in young (prepubertal) children and of cell membranes can activate relevant ion channels
directly [25]. Work by Fraser et al [26], Arieff et al [27],premenopausal women [15–17]. A further aggravating
factor is hypoxia; Ayus and Arieff postulated a vicious and Kozniewska et al [28] suggests that the hormonal
status in female rats alters the ionic composition of braincycle between hyponatremic brain edema and hypoxia
[18, 19]. Progression to death or permanent brain damage cells, which in turn can impair ionic volume regulation
and exacerbate brain edema, thereby decreasing brainis a common event in acute severe hyponatremia left
untreated [9, 19]. It is generally agreed that the acute perfusion, and increasing mortality in female rats.
An additional and essential decrease of brain volumehyponatremic syndrome should be treated rapidly. Ayus
and coworkers proposed an hourly correction rate of can be accomplished within the first two to four days by
reducing cellular osmolytes, substances that efficiently1.3 mmol/L, using 5% saline with furosemide while avoid-
ing correction to normo/hypernatremia and an increase transfer osmoles from the intracellular compartment to
the extracellular [25]. The osmolytes of brain cells in-of the serum sodium concentration by more than 25
mmol/L in the first 48 hours [20]. According to the litera- clude polyalcohols such as sorbitol and inositol, amino
acids, and methylamines [26]. Recent work in patientsture, this protocol is beneficial and does not cause brain
lesions of its own [21–23]. established the existence of osmolyte regulation in the
human brain. In 12 hyponatremic patients, proton mag-Animal models have been used to gain further insight
into cerebral edema in acute hyponatremia. Abrupt hypo- netic resonance spectroscopy demonstrated decreases of
cerebral osmolytes by as much as 50% [29]. In short, anosmolality (hyponatremia) of the extracellular space
causes an aquaporin-4 (AQP-4)-mediated osmotic water acute lowering of the serum osmolality will cause brain
edema until early and late cell volume adaptations havemovement into brain cells and swelling. Manley and
Verkman presented data at the Third International Con- been completed [30]. Because of the rigid skull, cerebral
edema can lead to increased intracranial pressure, de-ference on the Molecular Biology and Physiology of Wa-
ter and Solute Transport (Go¨teborg, 2000) indicating creased brain perfusion, and threatened respiratory in-
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sufficiency, and can result in herniation of the brain stem
into the foramen magnum [31], permanent brain dam-
age, or death [20]. Rapid correction of an acute hypona-
tremia is appropriate to avoid hyponatremic brain dam-
age. Rapid correction will restore brain cell volume to
normal [32]. In contrast, when chronic hyponatremia
is corrected, intracellular ions and osmolytes must re-
accumulate to return cell volume to normal.
Chronic severe hyponatremia
Occasionally, severe hyponatremia is present in a pa-
tient for months or even years [33]. Those patients are
usually oligosymptomatic or asymptomatic. It is not clear
that such patients should be treated. Much more com-
monly, patients will have had chronic, severe hypona-
tremia for only a few days, and it will have been associ-
ated with drowsiness, nausea, poor memory, or even
disorientation [34] (Table 1). The setting generally is
thiazide-induced hypokalemic hyponatremia; the syn- Fig. 3. Total increase of the serum sodium concentration over the first
drome of inappropriate antidiuretic hormone secretion 7 days of treatment of severe hyponatremia. Symbols are: ( ) 12 patients
with CPM; (), 9 patients without CPM. (Reproduced with permission(SIADH); liver cirrhosis, alcoholism, and malnourish-
from Williams & Wilkins, [36] Annals of Neurology 11:128–135, 1982.)ment; advanced, diuretic-treated cardiac failure; or pro-
tracted vomiting or diarrhea [35]. Physicians usually elect
to treat patients with such chronic severe hyponatremia.
For instance, it can be important to know whether a because the 12 index patients had a much lower baseline
hyponatremia than did the 9 so-called controls (106patient’s mental changes can be improved by correcting
hyponatremia. The physician might be concerned about mmol/L vs. 118 mmol/L). Several additional reports have
since appeared indicating that myelinolysis occurringa worsening of hyponatremia; or the need might exist
for large-volume infusions (hyperalimentation). Still, the after rapid correction of chronic hyponatremia can be
pontine or extrapontine [34, 35, 38, 40-42]. In one publi-treatment of chronic severe hyponatremia is controver-
sial because of the alleged possibility of inducing cerebral cation, 8 patients with chronic, severe, and symptomatic
hyponatremia had been treated at a correction rate ofmyelinolysis. In a retrospective study two decades ago,
Norenberg and colleagues described autopsy results 0.5 to 1.2 mmol/L/h (“rapid correction”); all developed a
syndrome compatible with CPM [34]. Of 55 comparablefrom 12 patients who had undergone “rapid” correction
(20 mmol/L over 1 to 3 days, occasionally reaching hyper- patients undergoing correction at less than 0.5 mmol/
L/h, however, none had any neurologic sequelae [34].natremia) [36]. The correction was followed in 3 to 10
days by central pontine myelinolysis (CPM). Most of the However, the study was retrospective. Furthermore, 7
of the 8 patients with CPM had thiazide-induced hypona-12 patients also had underlying chronic alcoholism, liver
disease (hepatitis, cirrhosis), or both, and these are inde- tremia with hypokalemia. Therefore, hypokalemia could
have been a precipitating co-factor of CPM. Other poten-pendent risk factors for CPM. Additional risk factors
for myelinolysis include malnutrition, thiazide therapy, tial problems with the interpretation of this study were
that 2 of the 8 patients with CPM were alcoholics; thehypokalemia, and hyponatremia 105 mmol/L [37–39].
Clinical consequences of CPM in these 12 patients in- hyponatremia in the 8 patients with CPM apparently
was more severe than that in the 55 uncomplicated pa-cluded a sudden disturbance in mental status, flaccid
quadriparesis, abnormal conjugate eye movements, and tients; and proof of demyelination [CT, magnetic reso-
nance tomography (MRT), autopsy] was missing in 4 ofpseudobulbar palsy [36]. When Norenberg et al com-
pared the 12 index patients with 9 others in whom the 8 patients with clinically diagnosed CPM. In another
study, Sterns et al surveyed the total experience withhyponatremia had been corrected more slowly (Fig. 3),
and in whom attainment of normo/hypernatremia had extreme hyponatremia (105 mmol/L) of 4100 U.S.
nephrologists [40]. Of the 56 patients reported, 14 hadbeen avoided, they found that none of the 9 had CPM,
as shown either by computerized tomography or autopsy. neurologic sequelae, potentially from myelinolysis. This
report indicates that severe hyponatremia is rare butThe authors concluded that CPM can be caused by a
too rapid or excessive rise in serum sodium from a hypo- that myelinolysis can occur in as many as 25% of such
patients. Most [38, 40–42] but not all recent publicationsnatremic baseline.
The Norenberg study is open to criticism, however, (abstract; Arieff, Ayus, J Am Soc Nephrol 10:19A, 1999)
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have indicated that cerebral demyelination is a complica- tionally described as the major part of the BBB [51]. This
specialized endothelium has tight intercellular junctions,tion of overly rapid correction of chronic hyponatremia.
Like cerebral edema, demyelination also has been most evident close to the luminal surface, where the cell
membranes fuse [51]. The vascular endothelium of theprobed in animal experiments. Verbalis and Martinez
studied a noninvasive rat model of hyponatremia (111 BBB is (electrically) much “tighter” than the “leaky”
capillary endothelia elsewhere. Astrocyte foot processesto 114 mmol/L; duration, 2 to 3 weeks) that is based on
administering DDAVP, a pure V2-vasopressin agonist also are an integral part of the BBB. In direct contact
with the basement membrane of the endothelium, they(AVP in humans is a V1/V2 agonist) [43]. Correction of
the hyponatremia from 118 mmol/L to 138 mmol/L within form a complete envelope around the capillaries. In-
creases in osmolarity in the form of forced hyperosmolar-48 hours by water restriction alone did not cause myelino-
lysis. Correction from 111 mmol/L to 143 mmol/L within ity have been known to disrupt the BBB [52, 53]. For
instance, intracarotid injection of 25% mannitol over8 hours by infusions of hypertonic saline (or by using a
vasopressin antagonist) was followed by focal or diffuse 3 minutes increased ipsilateral BBB permeability by
more than 100%, and the BBB disruption was pro-demyelination in 90% of the rats. When the normona-
tremia was reversed rapidly to a serum sodium level of portional to the degree of maximal hyperosmolarity
achieved. Kroll and Neuwelt hypothesized that shrink-111 mmol/L, only 45% of rats developed demyelination.
Similar findings also have been observed by other labora- age of cells of the BBB causes opening of the epithelial
“tight” junctions and retraction of astrocyte foot pro-tories [44].
The potential pathways by which such rapid correction cesses, all of which would lead to BBB disruption [53].
Disruption would permit access to the brain tissue, in-of chronic hyponatremia cause myelinolysis have been
studied. Attention has been given to organic osmolytes cluding myelinated neurons, of plasma constituents nor-
mally excluded. Myelinolysis would be a consequenceand their role in “osmotic reloading” of brain cells.
Thurston et al studied chronic (4-day) hyponatremia of this scenario.
Rojiani et al characterized BBB disruption in rats with(91 mmol/L) in young mice [45]. When the hyponatremia
was corrected to 134 mmol/L by hypertonic saline within chronic (4-day) severe hyponatremia, 8 hours after rapid
correction. They observed interendothelial gaps, dilation9 hours, the mice manifested dehydration and shrinkage
of the brain, normal brain levels of sodium and potas- of interendothelial spaces, swelling of astrocyte foot pro-
cesses, and extravasation of macromolecules such as per-sium, but amino acid content below normal. Lien et al
demonstrated that in the course of rapid correction of oxidase [54]. Later, degenerative changes of dying oli-
godendrocytes and vesicular disintegration of myelinchronic hyponatremia, re-accumulation of sodium and
chloride caused elevations of these ions above the nor- sheaths occurred [55]. Animal experiments could not
detect a similar chain of events when chronic hypona-mal range in brain cells (“overshoot”) [46]. This occurred
at a time that the re-accumulation of organic osmolytes tremia was corrected slowly [43]. Some investigators
have claimed that myelinolysis in animals is preventablewas seriously lagging behind. In another study [47], the
re-accumulation of organic osmolytes took as long as by glucocorticoid administration [56, 57].
Taken together, the one or more causes of demyelin-5 days. Exogenous osmolyte supplementation failed to
speed up osmolyte re-accumulation [48]. Potentially ac- ation in patients with severe hyponatremia are not clear.
Severe chronic hyponatremia can be a marker for possi-counting for this lag, the transport of organic osmolytes
depends in part on tonicity-responsive new transcription ble development of cerebral demyelination. Given that
there are dire consequences when myelinolysis does oc-and expression of genes for osmolyte transporters (ab-
stract; Woo et al, J Am Soc Nephrol 10:60A, 1999). In cur, I therefore recommend using a correction rate of
0.5 mmol/L/day, as suggested [34], and halting furtheryet another recent study, Lien found osmolyte re-accu-
mulation to be most seriously delayed in areas where correction when the serum sodium concentration rises
to 126 mmol/L to 130 mmol/L. When a grand mal seizuremyelinolysis was most pronounced (mid-brain, striatum)
[44]. Such work suggests a relationship between demye- occurs in a patient with a previously oligosymptomatic
severe chronic hyponatremia, I recommend an initiallination and osmolytes. Hypothetically, the culprit of
such effects is the blood-brain barrier (BBB). correction rate of 1.0 to 1.5 mmol/L/h for the first three
hours. One can use urea to correct hyponatremia [58]According to Kinne and others, organic osmolytes are
molecules that are compatible with normal structure and or one can lower the serum sodium level in the setting
of a “correction overshoot” (defined as a serum sodiumfunction of cellular proteins and lipids, as opposed to
high concentrations of inorganic ions [49, 50]. With re- concentration 148 mmol/L during the first 72 hours of
correction), but whether these maneuvers are of demon-spect to demyelination, the question appears to be: which
cells are likely to be altered by ionic overshoot and/or strable clinical benefit remains to be proven. Imaging
studies such as CT or MRT should be performed approx-deficiency of organic osmolytes? One class of cells af-
fected are the cerebral vascular endothelial cells, func- imately 6 to 12 days after correction of hyponatremia to
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Fig. 4. Left: Saggital T2-weighted nuclear
magnetic resonance (NMR) section showing
an oval-shaped region of discrete hyperinten-
sity in the center of the pons 9 days after onset
of clinical symptoms following correction of
hyponatremia. Right: follow-up examination
23 days after onset of clinical symptoms re-
vealing a distinct rise in signal intensity. (Re-
produced with permission from Springer-Ver-
lag, [38] Eur Radiol 6:177–183, 1996.)
determine whether suspected CPM is present (Fig. 4) excess coupled with continued fluid (hypotonic) intake
[59]. The excess vasopressin causes increased water reab-[38, 41]. The clinical presentation of myelinolysis is unre-
sorption by the kidney; thus, a fluid intake higher thanliable and occasionally takes an apparently asymptom-
minimal (that is, 600 to 800 cc/day) leads to water reten-atic course [38].
tion, dilution of all fluid compartments, and hypona-
Severe hyponatremia of uncertain duration tremia. The hyponatremia of volume contraction and
that of advanced renal insufficiency, which are relatedSometimes a patient will have severe hyponatremia
to different pathogenetic mechanisms, will not be amongof uncertain duration accompanied by symptoms and
the future indications for vasopressin antagonists.findings possibly resulting from hyponatremia. In such
Several oral, non-peptidic vasopressin antagonists areambiguous cases, it is impossible to know whether the
currently being studied (Table 2) (abstracts; Kuhn et al,risks of fast correction (myelinolysis) exceed those from
Kidney Blood Press Res 21:183, 1998; Abraham et al,slow correction (brain edema and damage). In this situa-
World Cong Neurohypophyseal Hormone, Montreal,tion, which has not been well studied, I suggest the fol-
1997, #183; Coupet et al, ibid, #181) [60, 61]. In cardiaclowing: If the patient is in a stable condition with mild
failure, vasopressin antagonists increase renal water ex-to moderate symptoms, I would consider an imaging
cretion (“aquaresis”) and improve hypo-osmolality andstudy (CT, MRT) to search for brain edema and/or cere-
hyponatremia (abstracts; Abraham et al, ibid; Naitohbral abnormalities; thereafter I would determine the rate
et al, ibid, #187) [62, 63]. In addition, a V2 antagonistof correction accordingly. If the patient is unstable and/or
improved cardiac failure in the dog [63, 64]. In moder-presented advanced symptoms or signs, or if the patient
ately advanced liver cirrhosis, V2 antagonists have in-is a symptomatic prepubescent child or a premenopausal duced aquaresis in animals [65] and in humans [61, 66].
woman, I would chose a correction rate of 1 to 2 mmol/ When Inoue and colleagues gave OPC-31260 to 8 pa-
L/h for three or four hours. I then would immediately tients with biopsy-proven cirrhosis, a hypotonic diuresis
perform an imaging study to direct subsequent treat- ensued and urinary flow rate approximately tripled [66].
ment. Admittedly, these suggestions are based on my However, renal function had to be watched closely for
personal observations only. signs of potential deterioration in cirrhotic patients given
another V2 antagonist [60]. Similarly, the hyponatremiaVasopressin antagonists of SIADH was improved by V2 antagonists in animals
Oral vasopressin antagonists are effective and poten- [67, 68] and humans [69]. None of the studies has re-
tially useful in the treatment of hyponatremia. These ported an effect of oral vasopressin antagonists on thirst
agents might allow better predictability and better fine- in humans. The treatment of hyponatremia can be ex-
tuning of treatment. Appropriate use of vasopressin an- pected to change when the new vasopressin antagonists
tagonists will require an understanding of the role of become available. However, the principles and guide-
vasopressin in hyponatremia. lines concerning the rate of correction and its potential
dangers, as discussed here, probably will not.Hyponatremia is primarily a disorder of vasopressin
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Table 2. Properties of V2 receptor antagonistsa
OPC 31260 SR 121463A VPA-985 YM 087b
Route of application oral oral oral oral
Ki in rats nmol/L 21.7 1.42 0.48 3.0
Ki in humans nmol/L 25.4 4.1 1.12 1.1
Selectivity index
(Ki-V1a/Ki-V2) 10 112 not determined 0.1
Urine volume ↑ (DD) ↑ (DD) ↑ (DD) ↑ (DD)
Urine osmolality ↓ (DD) ↓ (DD) ↓ (DD) ↓ (DD)
Na excretion/24 h unchanged unchanged unchanged at LD unchanged (↑ at HD)
K excretion/24 h unchanged unchanged unchanged at LD unchanged (↑ at HD)
Serum [Na] response ↑ ↑ ↑ ↑
Agonistic activity none none none none
Manufacturer Otsuka, Japan Sanofi, France Wyeth-Ayerst, USA Parke-Davis/Yamanouchi,
USA/Japan
a Abbreviations are: Ki-inhibition constant (concentration of antagonist required to inhibit 50% of maximal V2 effect of vasopressin; DD, dose dependent; LD,
low dose; HD, high dose
b YM 087 is a nonspecific vasopressin receptor antagonist
QUESTIONS AND ANSWERS I believe that the accompanying hypokalemia—a risk
factor for CPM—deserves mentioning. Overall, the riskDr. Nicolaos E. Madias (Executive Academic Dean,
for CPM appears to be greater with thiazide-inducedTufts University School of Medicine, Boston, Massachu-
hyponatremia than with other hyponatremic circum-setts, USA): Rapid correction of hyponatremia can occur
stances. One is usually dealing with a chronic form ofin other circumstances, such as water restriction in pri-
severe hyponatremia. In that setting, the electrolyte dis-mary polydipsia, volume repletion of volume-depleted
order should be corrected slowly. My bias is that potas-patients, dialysis against a bath with a sodium concentra-
sium replacement is also important in such patients.tion substantially higher than that of the patient, and
Dr. Madias: Considering the patient’s very severecortisol replacement of adrenal insufficiency. Could you
hyponatremia, could you please address our current un-please comment on the magnitude of the risk for CPM
derstanding of the signal for vasopressin escape? Arein these settings and measures that can limit the risk?
there situations in which failure of vasopressin escapeDr. Gross: The literature does contain some limited
might occur?information on psychogenic polydipsia [70–75]. Also,
Dr. Gross: Escape from vasopressin is a term used toSterns and coworkers mention rare patients with psycho-
describe the return of urinary osmolality to its baselinesis-, ethanol-, or Addison’s disease-induced severe, possi-
low levels despite continued elevation of vasopressin inbly chronic, hyponatremia (94 mmol/L to 100 mmol/L)
plasma. Vasopressin escape has only been studied inthat was corrected at 0.5 mmol/L/h and who then suf-
experimental animals. Using a DDAVP-induced modelfered coma, other neurologic sequelae, or death [34].
of SIADH in the rat, we found the signal for vasopressinBrunner et al reported a single patient with Addison’s
escape to be related to the degree of the hyponatremiadisease and CPM after correction [41], as did Shoji et al
and/or the accompanying plasma volume expansion butin a patient with Sheehan’s syndrome [76]. The risk in
not to vasopressin itself [80, 81]. In terms of potentialthese groups is probably small if the guidelines presented
mechanisms of escape, changes in PGE2 and aquaporin-2here are heeded. Soupart and colleagues have postulated
might contribute early in mild hyponatremia [80, 81].that uremia confers protection from the risk of brain
Hemodynamic changes such as increases of renal plasmadamage [77]. I would propose guiding therapy in any
flow and glomerular filtration rate (GFR) were media-such patients according to the chronicity of the hypo-
tors of the escape later in the setting of severe hypona-natremia, as I discussed previously.
tremia [80, 81]. Escape in other disorders such as cardiacDr. Madias: Could you comment on thiazide-induced
failure, hepatic cirrhosis, and volume depletion stateshyponatremia in this context?
has not been studied. I would expect vasopressin escapeDr. Gross: Thiazide-induced severe hyponatremia has
to be impaired in those disorders, even to the extent ofbeen reported frequently [12, 78, 79], including its associ-
escape failure, because GFR often is reduced and distalation with CPM (Fig. 4) [34, 35, 41, 42]. Usually, such
delivery of tubular fluid also is often decreased.patients are elderly women who have taken the thiazide
Dr. Madias: I would like to ask several questions withfor less than 2 weeks for hypertension [78]. Reportedly
respect to vasopressin antagonists. Is the therapeutic ef-there are signs of mild volume depletion upon presenta-
ficacy of AVP V2-receptor antagonists similar in hypona-tion. With respect to the mechanism(s) of this hypona-
tremic patients with SIADH compared to those withtremia, metolazone, a thiazide, was shown to turn a posi-
tive free-water clearance into a negative one [78]. edematous disorders? Is the risk of developing hyper-
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natremia while taking these medications more substan- bral blood vessels by vasopressin, causing a decrease of
brain perfusion in female but not in male rats [85].tial in elderly patients with hypodipsia, who depend on
others for ensuring their water requirements? Have you Dr. Eckardt: My other question relates to the patho-
physiology of the neurologic complications. Some dataencountered hypernatremia in your studies of vasopres-
sin antagonists? Finally, since the abundance of vaso- indicate that vasopressin has direct effects on the brain.
Is it possible that the inappropriate elevation of vaso-pressin receptors seems to change in relation to the
chronicity of the hyponatremia, have any studies in ani- pressin in hyponatremia has itself effects on the brain
beyond those of hyponatremia? Could this have futuremal models tested whether the effectiveness of vasopres-
sin antagonists is a function of the duration of hypo- implications for therapies with vasopressin antagonists?
Dr. Gross: Ayus and Arieff point out that there arenatremia?
Dr. Gross: In the study involving VPA-985, the V2 at least four separate direct effects of vasopressin on the
brain: (1) water movement into the brain; (2) decline inantagonist was more effective in the hyponatremia of
SIADH than that of liver cirrhosis or heart failure [60]. brain synthesis of ATP; (3) decreased brain blood flow;
and (4) impairment of sodium efflux during hypona-We have not encountered hypernatremia in either of
two investigations with vasopressin antagonists so far. tremia [10]. Whether these effects might have any bear-
ing on treatment of hyponatremia with vasopressin an-Vasopressin antagonists, however, could produce hyper-
natremia were their effects not monitored closely. Pre- tagonists has not been studied. It is conceivable that you
might well be right.cautions such as frequent measurement of the serum
sodium concentration are indicated, especially in pa- Dr. Eckardt: The ability to excrete water does not
depend merely on the kidney’s diluting capacity; it alsotients in whom the vasopressin antagonist is followed by
a large aquaresis. Your last question regarding a possible depends on the amount of solute to be excreted. The
case you presented reminds me of beer potomania. Inrelation between vasopressin V2-receptor density and
chronicity of the hyponatremia is difficult to answer; to such patients the caloric intake consists primarily of car-
bohydrates. Those patients are not eating protein, sothe best of my knowledge, it has not been studied.
Dr. Vladimir Teplan (Professor of Medicine and Ne- they do not excrete any sizable amounts of solute. Like
your patient, these people live on carbohydrates. Inphrology, Institute of Clinical Experimental Medicine,
Prague, Czech Republic): Disorders of the serum sodium retrospect, what would you have recommended in to-
day’s patient?concentration present problems in cadaveric organ do-
nors with brain death. In this situation, we usually ob- Dr. Gross: The patients described by Fenves et al
were binge-drinking alcoholics [79]. Reported daily vol-serve hypernatremia, sometimes up to 180 mmol/L. In a
minority of donors, however, we observe hyponatremia, umes of beer were in the range of 4 to 5 L. Nonetheless,
those patients presented with dry mucous membranes,which can be very difficult to treat. What are your expla-
nations for these two situations? low arterial blood pressure, tachycardia, very low urinary
sodium excretion rate, and hyponatremia. In one patient,Dr. Gross: Hypernatremia in a potential organ donor
is indeed not uncommon. It is reportedly caused by cen- the urinary osmolality was reportedly 50 mOsm/kg, that
is, maximally dilute. Vasopressin levels were not re-tral diabetes insipidus from brain death [82–84]. Your
remark concerning hyponatremia in brain-dead poten- ported. The authors explained the syndrome by excessive
daily intake of beer with minimal concurrent intake oftial organ donors is very intriguing. One report attributes
such hyponatremia to the administration of vasopressin solute. They recommended “salting the beer.” I find it
difficult to follow their interpretation. I wonder whetherand epinephrine [82]. In patients in whom the posterior
pituitary is working, adrenal insufficiency, severe hypo- in such patients nausea, vomiting, diarrhea, or cirrhosis
contribute to the hyponatremia. To answer your ques-thyroidism, cardiac failure, or liver cirrhosis occasionally
causes hyponatremia. tion: I would have stopped the glucose and switched to
heme therapy. Heme administration, (heme arginate,Dr. Kai-Uwe Eckardt (Associate Professor, Depart-
ment of Nephrology and Intensive Care, Humboldt-Uni- 3 mg/kg body weight IV once daily for 4 days) suppresses
the activity of hepatic -aminolevulinic acid synthase.versita¨t, Berlin, Germany): The patient you presented
today was a young lady. You mentioned several times Also, I would have interrupted the vomiting by medica-
tion. I do not see a compelling reason to supply proteinthat data indicate an increased risk in premenopausal
females for developing neurologic complications. What or amino acids with respect to the hyponatremia.
Dr. Eckhart Bu¨ssemaker (Nephrologist, Universita¨ts-is the mechanism of this phenomenon?
Dr. Gross: The work by Ayus and Arieff has shown klinikum C. G. Carus): You indicated that vasopressin
is important in generating hyponatremia. However, intwo pathogenetic mechanisms: inhibition of cerebral
Na,K-ATPase activity by estrogens with an impaired the patient presented, it appeared that you did not mea-
sure the plasma vasopressin concentration.ability of brain cells to extrude Na in the initial cell
volume defense, and increased vasoconstriction of cere- Dr. Gross: Surprisingly, measurements of the plasma
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vasopressin concentration usually are not helpful in the prudent to aim for a correction that does not exceed 8
mmol/L on any day of treatment. Depending on theordinary clinical management of severe hyponatremia.
The reasons for this are: (1) results are not available severity of the symptoms, the rate of correction can be
1 to 2 mmol/L/h for several hours with subsequent slow-on the same day; (2) in a study of 200 patients with
hyponatremia (134 mmol/L) we showed that almost ing of the pace of correction. Of course, if severe symp-
toms persist, one is obligated to exceed the targetedall had “elevated” vasopressin [59]; and (3) the interpre-
tation of vasopressin measurements is usually a source range of correction, the imminent risks of cerebral edema
outweighing the potential risk of CPM.of confusion. Physicians tend to forget about the relation
between vasopressin and osmolality. In hypo-osmolar Dr. Gross: As far as I know, all authors are in agree-
ment that cerebral edema deserves rapid correction ofhyponatremia, vasopressin is biologically suppressed,
that is, unmeasurable. Thus, if vasopressin can be mea- hyponatremia. Arieff and Ayus recently presented an
analysis of 270 patients with acute severe hyponatremiasured, as in almost all patients with hyponatremia, it is
elevated in the context of the prevailing hypo-osmolality, (110 mmol/L). They noted an hourly correction rate of
1.3 mmol/L, reaching 132  7 mmol by 31 hours ofeven if the level looks low for a normal plasma osmolal-
ity. Therefore, indeed, it is not necessary to measure the correction. There was no detectable relation between
the rate of correction and outcome (abstract; Arieff,plasma ADH concentration in the routine management
of severe hyponatremia. Ayus, J Am Soc Nephrol 10:119A, 1999). Your next point
was a total daily correction rate not to exceed 8 mmol/LDr. Jana Henschkowski (Physician, Universita¨tsklini-
kum C. G. Carus): In your study using vasopressin antag- in chronic oligosymptomatic hyponatremia. As far as I
know, no prospective data in the literature clearly sup-onists in patients, you were unable to predict the initial
aquaretic response to the antagonist. Could you specu- port such a suggestion. In fact, we might never be in a
position to test whether there is a difference betweenlate as to the causes of this failure?
Dr. Gross: As you implied, there was indeed no corre- your proposed correction rate and the standard rate
(0.5 mmol/L/h) with respect to CPM because CPMlation between initial plasma vasopressin concentration
and subsequent aquaretic response. The only exception occurring after correction of hyponatremia is a very rare
event. For instance, Sterns et al had to evaluate responsesto this was observed in the group of cirrhotic patients.
from 4100 participating nephrologists to be able to findThe degree of severity of hyponatremia also did not
14 cases with “neurologic sequelae” after treatment ofcorrelate with aquaresis. There could be several explana-
severe hyponatremia [35]. In addition, it is never possibletions for this. The plasma vasopressin concentration is
in such reports to fully exclude other underlying brainnot constant in a given hyponatremic patient; rather, it
pathologies and other clinical risk factors as causes ofvaries by as much as 50% within 24 hours. Also, fluid
“neurologic sequelae.” Thus, the usefulness of 0.3 mmol/intake, which differs among patients, affects the degree
L/h—as opposed to 0.5 mmol/L/h—will be very difficultof hyponatremia. Finally, factors such as GFR, distal
to confirm in randomized studies of chronic oligosympto-delivery of filtrate, and abnormalities of collecting duct
matic severe hyponatremia in the future. As far as severefunction influence water balance too.
symptomatic hyponatremia of uncertain duration is con-Dr. Madias: For a number of reasons, one can over-
cerned, I suggest an imaging study. The study often canshoot the mark of intended correction of severe hypona-
reveal the presence (or absence) of brain edema, whichtremia. Do data support the usefulness of returning se-
in turn could guide the corrective therapy.rum sodium to a lower level by administering hypotonic
fluids in this setting? Reprint requests to Dr. P. Gross, Nephrology, Medizinische Klinik
Dr. Gross: Studies in laboratory animals indicate that III, Universita¨tsklinikum Carl Gustav Carus, Fetscherstrasse 76, D-01307
Dresden, Germany.re-induction of a hyponatremia is beneficial after correc-
E-mail: peter.gross@mailbox.tu-dresden.detion overshoot [43, 77]. There are no comparable data
in humans.
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